Posted by Michael Wonder on 04 May 2023
Humacyte’s human acellular vessel receives FDA’s regenerative medicine advanced therapy designation for urgent arterial repair following vascular trauma
4 May 2023 - HAV granted second RMAT designation by the FDA.
Humacyte has been recently granted the US FDA’s regenerative medicine advanced therapy designation for its human acellular vessel for urgent arterial repair following extremity vascular trauma.
